Joint Declaration on the Security of Supply of Medical Radioisotopes

WE, the Ministers and representatives of Australia, Belgium, Canada, France, Germany, Japan, the Republic of Korea, the Netherlands, Poland, the Russian Federation, South Africa, Spain, the United Kingdom and the United States of America, SHARE a common interest in ensuring the security of supply of the most widely used medical radioisotope, molybdenum-99 (99Mo) and its decay product, technetium-99m (99mTc), which is used in approximately 40 million medical diagnostic imaging procedures per year worldwide enabling precise and accurate, early detection and management of diseases such as heart conditions and cancer, in a non-invasive manner.

WE ACKNOWLEDGE, on the one part, that the production of 99mTc depends largely on a small number of reactors that are ageing and facing unplanned outages, planned refurbishment outages or planned permanent shutdowns, which increases the risk of disruption of the supply chain, unless new infrastructure is developed to replace these facilities before they shut down.

WE RECOGNISE, on the other part, that an unsustainable economic structure is threatening the reliability of the 99Mo/99mTc supply chain, and that global action to move to full-cost recovery is necessary to ensure economic sustainability and long-term secure supply of medical isotopes.

WE AFFIRM that any action to ensure the reliability of supply of 99Mo/99mTc must be consistent with the political commitments to non-proliferation and nuclear security.

WE CONFIRM our acceptance of the principles set forth in the policy approach released in June 2011 by the High-Level Group on the Security of Supply of Medical Radioisotopes (the HLG-MR principles) to ensure the long-term secure supply of medical radioisotopes, which were formally endorsed by the Organisation for Economic Co-operation and Development's (OECD) Steering Committee for Nuclear Energy on 28 April 2011.

WE COMMIT, with the aim of jointly promoting an internationally consistent approach to ensuring the long-term secure supply of medical radioisotopes, to implement the HLG-MR principles in a timely and effective manner, and to:

WE INVITE the OECD Nuclear Energy Agency (NEA) to further the objectives set out in this Joint Declaration by, among other actions, undertaking periodic reviews of the progress of the supply chain with implementing the HLG-MR principles.

Last reviewed: 31 August 2015